Med25 is required for estrogen receptor alpha (ERα)-mediated regulation of human CYP2C9 expression

被引:7
|
作者
Shi, Zhe [1 ]
Yang, Wenjun [2 ]
Goldstein, Joyce A. [3 ]
Zhang, Shu-Yun [1 ]
机构
[1] Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, Dept Prevent Med, Wenzhou 325035, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325035, Zhejiang, Peoples R China
[3] NIEHS, Human Metab Sect, Lab Toxicol & Pharmacol, Natl Inst Hlth, Res Triangle Pk, NC 27709 USA
关键词
CYP2C9; Med25; ER alpha; Transcription regulation; CONSTITUTIVE ANDROSTANE RECEPTOR; PREGNANE-X-RECEPTOR; TRANSCRIPTIONAL REGULATION; GLUCOCORTICOID-RECEPTOR; MEDIATOR COMPLEX; COACTIVATOR COMPLEX; ACTIVATION; GENE; SUBFAMILY; PROMOTER;
D O I
10.1016/j.bcp.2014.06.016
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CYP2C subfamily of cytochrome P450 enzymes is an important class of drug metabolizing enzymes in human liver. CYP2C9 is the most abundant member of the human CYP2C subfamily in liver and metabolizes similar to 15% of the therapeutic drugs as well as other xenobiotics and endogenous compounds. A number of nuclear receptors including xenobiotic-sensing receptors such as the constitutive androstane receptor (CAR), pregnane X receptor (PXR), and glucocorticoid receptor (GR) as well as liver enriched receptors hepatic nuclear factor 4 alpha (HNF4 alpha) and the estrogen receptor alpha (ER alpha) regulate CYP2C9 expression. Here, we show that Med25, a variable component of Mediator complex, enhanced ligand dependent ER alpha-mediated transcriptional activation of CYP2C9 promoter and interacts with activated ERa by 17 beta-estradiol through its C-terminal LXXLL motif. In conclusion, Med25 is identified as a new coactivator of ER alpha that is required for ERa-mediated regulation of CYP2C9 expression. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:425 / 431
页数:7
相关论文
共 50 条
  • [31] Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes
    Miners, JO
    Coulter, S
    Birkett, DJ
    Goldstein, JA
    PHARMACOGENETICS, 2000, 10 (03): : 267 - 270
  • [32] Examination of glucocorticoid receptor α-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines
    Pavek, P.
    Cerveny, L.
    Svecova, L.
    Brysch, M.
    Libra, A.
    Vrzal, R.
    Nachtigal, P.
    Staud, F.
    Ulrichova, J.
    Fendrich, Z.
    Dvorak, Z.
    PLACENTA, 2007, 28 (10) : 1004 - 1011
  • [33] Discovery of new potentially defective alleles of human CYP2C9
    Blaisdell, J
    Jorge-Nebert, LF
    Coulter, S
    Ferguson, SS
    Lee, SJ
    Chanas, B
    Xi, T
    Mohrenweiser, H
    Ghanayem, B
    Goldstein, JA
    PHARMACOGENETICS, 2004, 14 (08): : 527 - 537
  • [34] Cooperativity of proximal HPF1 sites in regulation of human CYP2C9 by PXR/CAR
    Chen, YP
    Ferguson, SS
    Goldstein, JA
    DRUG METABOLISM REVIEWS, 2004, 36 : 306 - 306
  • [35] Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam
    Bonnabry, P
    Leemann, T
    Dayer, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 49 (04) : 305 - 308
  • [36] Clinical relevance of genetic polymorphisms in the human CYP2C9 gene
    Schwarz, UI
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 : 23 - 30
  • [37] The effects of folate supplementation on human CYP2C9 transactivation.
    Xie, HG
    Muszkat, M
    Stein, CM
    Kim, RB
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P15 - P15
  • [38] Analysis of CYP2C8, CYP2C9, CYP2C18 and CYP2C19 mRNA expression in human liver, small intestine, skin and leucocytes
    Laepple, F
    Griese, EU
    Zanger, U
    Thon, KP
    Eichelbaum, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (04) : R783 - R783
  • [39] New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4
    Mwinyi, Jessica
    Nekvindova, Jana
    Cavaco, Isa
    Hofmann, Yvonne
    Pedersen, Rasmus Steen
    Landman, Ellie
    Mkrtchian, Souren
    Ingelman-Sundberg, Magnus
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (03) : 415 - 421
  • [40] Involvement of hepatocyte nuclear factor 4α in the different expression level between CYP2C9 and CYP2C19 in the human liver
    Kawashima, Sachiyo
    Kobayashi, Kaoru
    Takama, Kaori
    Higuchi, Tomoaki
    Furihata, Tomomi
    Hosokawa, Masakiyo
    Chiba, Kan
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (06) : 1012 - 1018